<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20120913010826N33</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-06-12</date_registration>
      <primary_sponsor>Research Assistant, Yazd University of Medical Sciences</primary_sponsor>
      <public_title>Effect of legume-based DASH diet in patients with polycystic ovary syndrome</public_title>
      <acronym></acronym>
      <scientific_title>The effects of legume-based DASH diet on anthropometric factors, glucose &amp; lipid profiles and testosterone level in women with polycystic ovary syndrome (PCOS): A randomized clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-06-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>54</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/70572</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: The term "legumes" includes legumes, soybeans, peas, beans, etc, Randomization description: The stratified randomization method is used for random allocation. Therefore, we first classify BMI into three groups: standard, overweight, and obese, and then use a simple random assignment method in each group.
First, eligible people are classified into BMI groups, and then in each BMI group, the first eligible person is number 1 and the next person is number 2, and so on until the 27th person. Random Allocation software version 1 is used to prepare the random allocation list.</study_design>
      <phase>3</phase>
      <hc_freetext>polycystic ovary syndrome.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:  Legume-based DASH diet. DASH diet (Dietary Approaches to Stop High Blood Pressure) that contains 50-55% carbohydrates, 15-20% protein and 25-30% fat. The DASH diet is high in fruits, vegetables, whole grains, and low-fat dairy, and low in saturated fat, cholesterol, and refined grains. In the legume-based DASH diet, we replace up to 1 to 3 units of meat and grains with more legumes and soybeans. The calories needed by each patient are estimated based on the basal metabolic rate (using the Harris-Benedict equation) and the levels of physical activity and energy resulting from food metabolism. For people who are overweight or obese, a caloric restriction of 500 to 700 kcal less than the calculated energy requirement for each person is considered. 500 kcal for those whose BMI is in the range of 25-31 kg/m2 and 700 kcal for those with a BMI greater than 31 kg/m2 will be deducted from the total energy needed by each person, and weight loss is intended for these people. The replacement list is provided to the patient while educating the patient to make it easier to choose foods and comply with the principle of diversity between the components of each food group. Intervention 2: Control group: A standard diet that contains 50-55% carbohydrates, 15-20% protein and 25-30% fat. The calories needed by each patient are estimated based on the basal metabolic rate (using the Harris-Benedict equation) and the levels of physical activity and energy resulting from food metabolism. For people who are overweight or obese, a caloric restriction of 500 to 700 kcal less than the energy requirement calculated for each person is considered. 500 kcal for people whose BMI is in the range of 25-31 kg/m2 and for people whose BMI is more than 31 kg/m2, 700 kcal is deducted from the total energy requirement of each person, and weight loss for These people are considered. The replacement list is provided to the patient while educating the patient to make it easier to choose foods and comply with the principle of variety between the components of each food group.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is It is not yet known if there will be a plan to make this available</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr Azadeh Najarzadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shohaday-e-Gomnam Blvd., Alem Sq., Yazd, Iran</address>
        <city>Yazd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8915173160</zip>
        <telephone>+98 35 3149 2232</telephone>
        <email>azadehnajarzadeh@gmail.com</email>
        <affiliation>Yazd University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Azadeh Najarzadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shohaday-e-Gomnam Blvd., Alem Sq., Yazd, Iran</address>
        <city>Yazd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8915173160</zip>
        <telephone>+98 35 3149 2232</telephone>
        <email>azadehnajarzadeh@gmail.com</email>
        <affiliation>Yazd University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Women of reproductive age and before menopause (20-50 years)
Women with PCOS according to the Rotterdam criteria
Oligomenorrhea or amenorrhea
Clinical or laboratory hyperandrogenism</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>50 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Pregnancy, miscarriage or breastfeeding in the last 6 months
Oligomenorrhea caused by secondary causes, including endocrine disorders (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome, hyperprolactinemia, adrenal disorders)
Previous history or current getting with any cancer
History of type 2 diabetes
Intrauterine Insemination (IUI) or In Vitro Fertilization) IVF(
Special diets or low-calorie diets in the past three months, including vegetarian diets</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E28.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Polycystic ovarian syndrome</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Lifestyle</i_code>
      <i_code>Lifestyle</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:  Legume-based DASH diet. DASH diet (Dietary Approaches to Stop High Blood Pressure) that contains 50-55% carbohydrates, 15-20% protein and 25-30% fat. The DASH diet is high in fruits, vegetables, whole grains, and low-fat dairy, and low in saturated fat, cholesterol, and refined grains. In the legume-based DASH diet, we replace up to 1 to 3 units of meat and grains with more legumes and soybeans. The calories needed by each patient are estimated based on the basal metabolic rate (using the Harris-Benedict equation) and the levels of physical activity and energy resulting from food metabolism. For people who are overweight or obese, a caloric restriction of 500 to 700 kcal less than the calculated energy requirement for each person is considered. 500 kcal for those whose BMI is in the range of 25-31 kg/m2 and 700 kcal for those with a BMI greater than 31 kg/m2 will be deducted from the total energy needed by each person, and weight loss is intended for these people. The replacement list is provided to the patient while educating the patient to make it easier to choose foods and comply with the principle of diversity between the components of each food group.</i_keyword>
      <i_keyword>Control group: A standard diet that contains 50-55% carbohydrates, 15-20% protein and 25-30% fat. The calories needed by each patient are estimated based on the basal metabolic rate (using the Harris-Benedict equation) and the levels of physical activity and energy resulting from food metabolism. For people who are overweight or obese, a caloric restriction of 500 to 700 kcal less than the energy requirement calculated for each person is considered. 500 kcal for people whose BMI is in the range of 25-31 kg/m2 and for people whose BMI is more than 31 kg/m2, 700 kcal is deducted from the total energy requirement of each person, and weight loss for These people are considered. The replacement list is provided to the patient while educating the patient to make it easier to choose foods and comply with the principle of variety between the components of each food group.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>HOMA-IR index. Timepoint: Before intervention and 16 weeks after intervention. Method of measurement: HOMA-IR = (Glu ×Insulin)/405.</prim_outcome>
      <prim_outcome>Low density lipoprotein cholesterol (LDL). Timepoint: Before intervention and 16 weeks after intervention. Method of measurement: Special kit.</prim_outcome>
      <prim_outcome>High density lipoprotein cholesterol (HDL). Timepoint: Before intervention and 16 weeks after intervention. Method of measurement: Special kit.</prim_outcome>
      <prim_outcome>Triglyceride. Timepoint: Before intervention and 16 weeks after intervention. Method of measurement: Special kit.</prim_outcome>
      <prim_outcome>Total cholesterol. Timepoint: Before intervention and 16 weeks after intervention. Method of measurement: Special kit.</prim_outcome>
      <prim_outcome>FBS. Timepoint: Before intervention and 16 weeks after intervention. Method of measurement: Special kit.</prim_outcome>
      <prim_outcome>Serum insulin. Timepoint: Before intervention and 16 weeks after intervention. Method of measurement: Special kit.</prim_outcome>
      <prim_outcome>Free testosterone. Timepoint: Before intervention and 16 weeks after intervention. Method of measurement: Special kit.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Weight, fat mass, fat free mass, RMR, body mass index and visceral fat. Timepoint: Before intervention and 16 weeks after the intervention. Method of measurement: Omron digital Scale.</sec_outcome>
      <sec_outcome>Waist,Hip circumference. Timepoint: Before intervention and 16 weeks after the intervention. Method of measurement: Meter.</sec_outcome>
      <sec_outcome>Total energy intake, total nutrients intake. Timepoint: Before intervention and 16 weeks after the intervention. Method of measurement: 24 hour recall.</sec_outcome>
      <sec_outcome>The length of the menstrual cycle. Timepoint: Before intervention and 16 weeks after the intervention. Method of measurement: questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Research Assistant, Yazd University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-05-28</approval_date>
        <contact_name>Ethics committee of School of Public Health, Shahid Sadoughi University of Medical Sciences,</contact_name>
        <contact_address>Shohaday-e-Gomnam Blvd., Alem Sq., Yazd, Iran Yazd Yazd Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
